There was no revenue recorded for the fourth quarter or full year ended December 31, 2024, compared to $1.0 million in the year ended December 31, 2023. Revenue in 2023 was related to a milestone ...

The provincial government says Phase 1 of its Belleville Terminal Redevelopment Project in Victoria’s Inner Harbour is ...

SentinelOne, Inc. faces downside risk amid weak guidance, macro uncertainties, and limited catalysts. Click here for more on ...

Google publicly announced yesterday via the Android Developers account on Twitter that the new release was coming today. The ...

Landmark exclusive option and license deal with Takeda for ACI-24.060 with $100 million upfront and additional potential milestones of up to about $2.1 billion plus royalties on sales upon ...

Condominiums that have failed to complete their milestone inspections are the target of a new bill making its way through ...

Phase 3 AURORA trial of Descartes-08 in myasthenia gravis on track to commence in 1H25; Deep and durable responses maintained over 12 months in ...

AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update Landmark exclusive option and license deal with Takeda for ACI-24.060 with $100 million upfront and additional potent ...

Recently announced positive data from pivotal randomized, placebo-controlled phase 3 clinical trial of CAN-2409 in intermediate-to-high risk, ...

Novo Nordisk NVO announced disappointing data from a phase III study on a novel obesity candidate, CagriSema. Roche RHHBY ...

Grain to Tilbury will upgrade the existing electricity network by replacing the existing Thames Cable Tunnel, linking Tilbury ...

Dyne Therapeutics’ DYNE-101 shows positive results in phase 1/2 ACHIEVE study. Read why DYN stock may rise with FDA approval and a $2.78B market opportunity.